For Allocators
Lexi Ventures is a top-20 investor in gene tech startups.
This focus is rooted in these beliefs.
Genetic engineering will change the lives of all people to a degree comparable with the industrial and info-tech revolutions.
This will enable startups to create unmatched opportunities for wealth creation for their customers, employees, and investors.
The converging factors of falling costs, growing talent, protein modeling, and harnessing CRISPR have made this the right time for the thesis.
In the coming 10 years, there will be more alpha in gene tech than general AI, health, or climate VC investments.
Gene tech startups aim to cure many of the worst and most expensive diseases, improving happiness and reducing healthcare needs. Other gene tech startups will enable plants and microbes to produce newer and better things while sustaining the natural environment.
Lexi Ventures is one of the only investors concentrated exclusively in gene tech with diversification across industries.
For Startups
Lexi Ventures provides seed stage funding for US-based startups applying or enabling genomics or synthetic biology.
Most investments that Lexi Ventures considers are naturally described using the key words DNA, RNA, protein, or cell.
Lexi Ventures occasionally considers pre-seed funding rounds of particularly promising companies and post-seed rounds with particularly attractive terms.
Please connect if you are working on any of these.
A novel type of cell or gene therapy
Diagnostics using DNA, RNA, or proteins
Engineered vaccines
Genetically engineered things to eat
Engineered biotic cosmetics
Microbial processing of materials or chemicals
Software, data, chemistry, devices, processes, or IP supporting any of the above
Lexi Ventures tends not to invest in
Small molecules
Single asset therapeutics
Medical devices
Consumer-facing software
Jonah Probell
Managing Partner
Jonah manages the investments for Lexi Ventures. Prior to finance, he held engineering, executive, and founder roles in 7 startups. He achieved 2 IPOs, 16 granted patents and wrote 2 books.
Jonah has a lifelong interest in science, engineering, economics, philosophy, and the history of human technological development.
Jonah takes a rational, methodical approach to investing for maximum realized IRR. This mirrors a decade of experience building patent portfolios.
